Noxogen Nitric Oxide Formulation

About SynDermix

SynDermix operates as a specialized life science holding company, employing a venture capital-like model to identify, develop, and commercialize innovative assets in dermatology, drug delivery, and related fields. Its strategy involves creating separate subsidiary companies for each asset, such as BioEleSonic (medical devices), Noxogen Therapeutics (topical nitric oxide), and TheraLect (plant lectin therapies), aiming to de-risk and enhance value before a transaction. The company has a history dating back to 2009, has completed at least one transaction (Énielle® in 2019), and is led by Dr. Konstantinos Efthymiopoulos. As a private entity with a diversified, early-stage portfolio, its success hinges on advancing its subsidiaries' technologies through development and achieving lucrative partnerships or exits.

Therapeutic Areas